Abstract

Purpose: To survey the value of MRI in diagnosing ovarian tumors according to O-RADS MRI risk stratification system 2022. Material and Methods: Cross-sectional descriptive study on 46 patients with ovarian tumors treated at Hue Central Hospital from May 2022 - May 2023. Results: The study included 46 cases of ovarian tumors in the study, there were 8 malignant cases (17.39%), 38 benign cases (82.61%). Lesion with solid tissue and enhancing tissue were signs suggesting malignant tumors, with sensitivity of 100% and 75%, specificity of 76.32% and 88.89%. Applying O-RADS to diagnose ovarian tumors, the malignancy rate was 0% for tumors with O-RADS grade 2, 0% for tumors with O-RADS grades 3, 42.86% for tumors with O-RADS grade 4, 71.43% for tumors with O-RADS grade 5. Sensitivity Se = 100%, specificity Sp = 84.21%, positive predictive value PPV = 57.14%, negative predictive value NPV = 100%, accuracy Acc = 86.96%. Conclusion: Magnetic resonance has high value in diagnosing ovarian tumors. The application of O-RADS assigns a probability of malignancy based on the MRI features of an adnexal lesion and provides information to facilitate optimal patient management and enable improved interpretation agreement and standardized communication between radiologists and referring physicians